<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The diagnosis of primitive <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> depends on a panel of monoclonal antibodies which is growing over time </plain></SENT>
<SENT sid="1" pm="."><plain>The distinction between immature (lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath>) and mature <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is sometimes difficult </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we evaluated anti-TdT antibody in the diagnosis and classification of these proliferations </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: 13 lesions were examined by immunohistochemistry: 4 B and T lymphoblastic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 2 Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 5 B and T <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> and 2 <z:hpo ids='HP_0004845'>acute monoblastic leukemias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: TdT expression is specific of immature lymphoid proliferations (T or B lymphoblasts) </plain></SENT>
<SENT sid="5" pm="."><plain>TdT is not expressed by mature B or T cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> such as Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Significant numbers of cases of <z:hpo ids='HP_0004808'>acute myeloblastic leukemias</z:hpo> are TdT positive but could be easily distinguished from lymphoblastic proliferations </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Anti-TdT antibody represents a useful marker for differentiating <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> from other <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>This marker, available in routine diagnosis should be systematically included in the panel of antibodies used for immunophenotyping <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>